Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients

Type1 Diabetes Mellitus Clinical Trial

— T1DM AP  

Official title:

Restoring Brain Metabolism and Function in Older Adult T1DM Patients Using an AP System

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03353792
• Other study ID #: 2000020059
• Secondary ID: 1R01DK101984-01A
• Status: Terminated
• Phase: N/A
• Start date: November 1, 2017
• Est. completion date: August 28, 2019

Study information

• Verified date: November 2022
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate that a new insulin pump system can prevent low glucose episodes and improve brain function in aged Type 1 diabetes mellitus subjects.

Description:

The goals of this proposal are to implement a Close-Loop/Artificial Pancreas (CL/AP) system in older patients with type 1 diabetes mellitus (T1DM) in order to reverse brain metabolic adaptations and restore metabolic sensitivity, hypoglycemia awareness and appropriate hormonal counterregulatory responses (CRR). For purposes of this study we are looking to enroll aged T1DM subjects under insulin pump treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: August 28, 2019
• Est. primary completion date: August 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• Provide signed and dated informed consent form

• Male or female

• Age 50-75 years (at least 50% over the age of 65)

• T1DM (>20 years duration)

• C-peptide undetectable

• HbA1c of < 8%

• Insulin pump therapy

• History of frequent hypoglycemia with unawareness (defined as 2 or more episodes of severe hypoglycemia within one year requiring assistance) and 2 or more glucose values < 54 mg/dL during the week of Continuous Glucose Monitoring (CGM) (iPRO monitor, Medtronic) prior to enrollment

• BMI <27 kg/m2

• Good general health as evidenced by medical history and blood screening

• Willing to comply with all study procedures and be available for the duration of the study

• Willing to fast for a limited time period on the morning of a clamp study

Exclusion Criteria:

• Significant diabetic complications (untreated proliferative retinopathy, creatinine =1.5 mg/dl, urinary albumin levels 300 mg/day, autonomic neuropathy, painful peripheral neuropathy)

• Significant alcohol intake and vegetarian diet since both are known to have an impact on counterregulation and brain metabolism

• Any contraindications for MRI scanning, including presence of metallic implants or claustrophobia.

• Heavy exercise on a regular basis (i.e. marathon runners)

• Known allergic reactions to components of the study product(s)

• Treatment with another investigational drug or other intervention

• Active infection including hepatitis C, hepatitis B, HIV

• Any past or current history of alcohol or substance abuse

• Psychiatric or neurological disorders under active treatment

• Baseline hemoglobin < 10.5 g/dL in females, or < 12.5 g/dL in males. Blood donation within 30 days of the study

• History of coagulopathy or medical condition requiring long-term anticoagulant therapy (low-dose aspirin treatment is allowed)

• Co-existing cardiac, liver, and kidney disease

• Abnormal liver function tests

• Women that are on oral contraceptives, post-menopausal, pregnant (as assessed by pregnancy test that will be performed on female participants at reproductive age), or lactating.

• Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type1 Diabetes Mellitus

Intervention

Device:
• CL/AP system
CL/AP system enabled insulin pump/CGM combination
• usual diabetic care
usual diabetic care (insulin pump therapy) along with CGM recording

Locations

Country	Name	City	State
United States	Yale New Haven Hospital	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain Alternate Fuel Uptake	Change in brain alternate fuel uptake under hypoglycemia was measured by assessing the percent enrichment of Glutamine 4 (Gln4). Change was measured by subtracting follow up from baseline.; Astrocytic glutamine C4 enrichment is a measure of brain acetate metabolism (an alternate fuel to glucose). Previous studies have shown that in people who have been exposed to frequent hypoglycemic episodes, glutamine C4 enrichment increases. Therefore, we expected a reduction in Glutamine C4 percent enrichment in the follow up NMR scans in the intervention group who avoided frequent hypoglycemic episodes through the CL/AP system. In addition, there is no specific cut off value used for Glutamine C4 enrichment, rather a change or reduction was expected and noted."	Baseline to 8 - 10 weeks
Secondary	Change in Cognitive Function: MOCA	The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal. Change was calculated by subtracting follow up from baseline. https://www.parkinsons.va.gov/resources/MoCA-Instructions-English.pdf	Baseline to 8-10 weeks
Secondary	Change in Cognitive Function: Trail Test A	Trail making test (TMT) A is a test of visual attention and task switching. It provides information about visual search speed, speed of processing and executive function. Time is measured in seconds. The typical average time to complete the test is 29 seconds, a "deficient" performance would be >78 seconds; most people are able to complete in 90 seconds. Change was calculated by subtracting follow up from baseline.	Baseline to 8-10 weeks
Secondary	Change in Cognitive Function: Trail Test B	Trail making test (TMT) B is a test of visual attention and task switching. It provides information about visual search speed, speed of processing and executive function. Time will be measured in seconds. The typical average time to complete the test is 75 seconds, a "deficient" performance would be >273 seconds; most people are able to complete in 180 seconds. Change was calculated by subtracting follow up from baseline.	Baseline to 8-10 weeks
Secondary	Change in Cognitive Function: Grooved Pegboard Test	The grooved pegboard test is a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consists of a small board of holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. The task was completed using the dominant hand. Time was measured in seconds.	Baseline to 8-10 weeks